NCT06498518
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06498518
Title A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer (PRIMUS006)
Acronym PRIMUS006
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Karen Carty
Indications
Therapies
Age Groups: adult | senior
Covered Countries GBR

Facility Status City State Zip Country Details
University Hospitals Bristol NHS Foundation Trust Bristol United Kingdom Details
University Hospitals Coventry & Warwickshire Coventry CV2 2DX United Kingdom Details
Beatson West of Scotland Cancer Centre Glasgow G12 0YN United Kingdom Details
Royal Free London Hospital London United Kingdom Details
Royal Marsden Hospital London United Kingdom Details
The Christie Hospital Manchester United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field